Department of Anaesthesiology, Cliniques Universitaires St Luc, University Catholic of Louvain, Brussels, Belgium.
Department of Anaesthesiology, Cliniques Universitaires St Luc, University Catholic of Louvain, Brussels, Belgium.
Br J Anaesth. 2022 Apr;128(4):734-741. doi: 10.1016/j.bja.2021.11.043. Epub 2022 Feb 23.
Pain after resolution of peripheral nerve block, known as 'rebound pain' (RP), is a major problem in outpatient surgery. The primary objective was to evaluate the benefit of intraoperative ketamine at an anti-hyperalgesic dose on the incidence of rebound pain after upper limb surgery under axillary plexus block in ambulatory patients. The secondary objective was to better understand the rebound pain phenomenon (individual risk factors).
In this prospective, double-blind study, patients were randomised to receive either a single dose of i.v. ketamine (0.3 mg kg) or a placebo. Preoperative mechanical temporal summation and central sensitization inventory were applied to question underlying central sensitisation. Pain catastrophising and Douleur Neuropathique 4 questionnaires were used. Rebound pain was defined as pain intensity score >7 (numeric rating scale, 0-10) after block resolution. Postoperative pain was recorded at Days 1, 4, and 30 after discharge.
A total of 109 subjects completed the study, and 40.4% presented with rebound pain. Ketamine administration did not reduce rebound pain incidence or intensity. Temporal summation and central sensitisation inventory scores did not differ between subjects with and without rebound pain. The predictive risk factors were bone surgery (odds ratio [OR]=5.2; confidence interval [CI], 1.9-14.6), severe preoperative pain (OR=4.2; CI, 1.5-11.7), and high pain catastrophising (OR=4.8; CI, 1.0-22.3). At Day 30, the average daily pain was higher in the rebound pain group involving neuropathic characteristics.
Ketamine at an anti-hyperalgesic dose showed no benefit on rebound pain development. Although central sensitisation might not be involved, preoperative pain intensity, and catastrophising stand as risk factors. Because rebound pain remains frequent despite adequate procedure-specific postoperative analgesia, future studies should focus on patient-specific pain management.
外周神经阻滞消退后出现的疼痛,即“反弹痛”(RP),是门诊手术中的一个主要问题。主要目的是评估术中给予抗痛觉过敏剂量的氯胺酮对上肢手术腋丛阻滞下门诊患者反弹痛发生率的影响。次要目的是更好地了解反弹痛现象(个体危险因素)。
在这项前瞻性、双盲研究中,患者随机接受单次静脉注射氯胺酮(0.3mg/kg)或安慰剂。术前应用机械性时间总和和中枢敏化量表评估潜在的中枢敏化。使用疼痛灾难化和神经病理性疼痛 4 问卷。反弹痛定义为阻滞消退后疼痛强度评分>7(数字评分量表,0-10)。术后疼痛在出院后第 1、4 和 30 天记录。
共有 109 例患者完成了研究,40.4%的患者出现反弹痛。氯胺酮给药并未降低反弹痛的发生率或强度。有反弹痛和无反弹痛的患者时间总和和中枢敏化量表评分无差异。预测危险因素包括骨手术(比值比[OR]=5.2;置信区间[CI],1.9-14.6)、术前严重疼痛(OR=4.2;CI,1.5-11.7)和高疼痛灾难化(OR=4.8;CI,1.0-22.3)。在第 30 天,反弹痛组的平均每日疼痛更高,且具有神经病理性特征。
抗痛觉过敏剂量的氯胺酮对反弹痛的发展没有益处。尽管可能不涉及中枢敏化,但术前疼痛强度和灾难化是危险因素。由于尽管采用了特定于手术的术后镇痛,但反弹痛仍然很常见,因此未来的研究应侧重于患者的疼痛管理。